Effect of losartan on human platelet activation

Journal of Hypertension

Volumn 17, Issue 3, 1999, Pages 447-452

  Guerra Cuesta, José I ^a   Montón, Mercedes ^a   Rodríguez Feo, Juan A ^a   Jiménez, Ana M ^a   González Fernández, Fernando ^a   Rico, Luis A ^a   García, Rosa ^a   Gómez, Juan ^a   Farré, Jerónimo ^a   Casado, Santos ^a   López Farré, Antonio ^a,b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Clínica Nuestra Señora de la Concepción   (Spain)

Author keywords

Angiotensin I converting enzyme inhibitors; Angiotensin II; AT1 receptors; Platelets; Thromboxane A2

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; THROMBOXANE A2; TRITIUM;

ARTICLE; HUMAN; HUMAN CELL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA;

EID: 0033013923     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917030-00019     Document Type: Article

References (25)

1. 1 Timmermans PBWM, Wong PC, Chiu AT. Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45:205-251.
2. 2 Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346:1403-1407.
3. 3 Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, et al. Nonpeptide angiotensin II receptor antagonist: VIII. Characterization of functional antagonist displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252:719-725.
4. 1 receptors on human platelets and decreased angiotensin II binding in hypertension. J Hypertens 1993; 11:5230-5231.
5. 5 Moore TJ, Williams GH. Angiotensin II receptors on human platelets. Circ Res 1981; 51:314-320.
6. 6 Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al., on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE). Lancet 1997; 349:747-752.
7. 7 Hammon JW, Oates JA. Interaction of platelets with the vessel wall in the pathophysiology of sudden cardiac death. Circulation 1986; 73:224-226.
8. 8 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72:2294-2298.
9. 9 Patrono C, Renda G. Platelet activation and inhibition in unstable coronary syndromes. Am J Cardiol 1997; 80:17E-20E.
10. 2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 1997; 281:1065-1070.
11. 2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. J Pharmacol Exp Ther 1994; 268:747-752.
12. 12 Sánchez de Miguel L, Casado S, Farré J, Garcia-Durān M, Rico L, Monton M, et al. Comparison of in vitro effects of trifusal and acetylsalicylic acid on nitric oxide synthesis by human neutrophils. Eur J Pharmacol 1998; 343:57-65.
13. 13 López-Farré A, Riesco A, Digiuni E, Mosquera JR, Caramelo C, Sánchez de Miguel L, et al. Aspirin-stimulated nitric oxide production by neutrophils after acute myocardial ischemia in rabbits. Circulation 1996; 94:83-87.
14. 2 receptor antagonists. Thromb Res 1986; 41:471-481.
15. 15 Corriu C, Bernard S, Schott C, Stoclet JC. Effects of losartan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol 1995; 26:688-692.
16. 16 Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989; 74:1181-1190.
17. 17 Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7:1035-1040.
18. 18 Burrell LM, Johnston CI. Angiotensin II receptor antagonists: potential in elderly patients with cardiovascular disease. Drugs Aging 1997; 10:421-434.
19. 19 López-Farré A, Caramelo C, Esteban A, Alberola ML, Millás I, Montȯn M, et al. Effects of aspirin on platelets - neutrophil interactions: role of nitric oxide and endothelin-1. Circulation 1995; 91:2080-2088.
20. 20 Marcus AJ, Safier LB. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J 1993; 7:516-522.
21. 21 Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43:109-141.
22. 2stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31:349-355.
23. 23 Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin - angiotenin system and fibrinolytic function. Circulation 1993; 87:1969-1973.
24. 24 Ding YA, MacIntyre DE, Kenyon CJ, Semple PF. Angiotensin II effects on platelet function. J Hypertens 1985; 3 (Suppl 3):S251-S253.
25. 25 Burnier M, Centeno G, Grouzmann E, Walker P, Waeber B, Brunner HR. In vitro effects of DuP 753, a nonpeptide angiotensin II receptor antagonist, on human platelets and rat vascular smooth muscle cells. Am J Hypertens 1991; 4:438-443.